AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 91 min read$GOSS

Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M

Gossamer Bio (GOSS) announced a 1-for-80 reverse stock split and reduced authorized shares to 50M to comply with Nasdaq's minimum bid price requirement. The split is effective September 10, 2026, with trading adjustments on September 11, 2026. Convertible notes, warrants, and equity awards will be proportionately adjusted.

Original reporting
tradingview.com
Published Sep 9, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M — source image
Source · tradingview.com
Decision brief

The 30-second read

$GOSSNeutralMed
01

Why it matters

The reverse split is a compliance‑driven corporate action aimed at preventing delisting. It adjusts all outstanding securities proportionally.

02

Market read

The filing is the first public disclosure of the split, making it a primary corporate‑action news item.

03

What to watch

Potential impact on existing warrant and convertible note structures.

Relevance 6/10Novelty 8/10Timing: effective Sept 10, 2026 (split‑adjusted trading on Sept 11)

Background

Gossamer Bio is a clinical‑stage biotech trading under the ticker GOSS. The company faced Nasdaq bid‑price compliance issues.

Company-level read

Ticker impact

$GOSSNeutralHigh confidence
Context

Gossamer Bio filed an 8‑K announcing a 1‑for‑80 reverse stock split and reduction of authorized shares to 50 M.

Expected impact

Short‑term volatility expected; price likely to rise modestly as the split takes effect.

Evidence & confidence

Reverse splits are typically neutral to slightly positive for compliance‑driven micro‑caps; the move is disclosed for the first time.

Market effects

Sector

Minimal; primarily affects Nasdaq‑listed micro‑caps concerned with bid‑price compliance.

Regional

U.S. market only; no broader regional effect.

Global

Low; isolated corporate action.

Counterpoint

What could challenge this read

The split may not improve liquidity and could attract short‑selling pressure.

Key entities

  • company
    Gossamer Bio, Inc.

    Biotech issuer filing the reverse split.

Read at source← All news

Related articles

AUG 27
$GOSSMedAI 8/10

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

insidermonkey.com3 min
AUG 21
$GOSSHighAI 9/10

Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval

Gossamer Bio secured up to $250M in financing, including $150M committed capital and $100M in potential warrants, to fund seralutinib through FDA approval for pulmonary arterial hypertension. The company plans to use the funds for clinical trials, potential commercialization, and corporate needs, aiming to submit an NDA in September 2026. Investors include EcoR1 Capital, 683 Capital Partners, and others.

pulse2.com2 min
AUG 21
$GOSSHighAI 9/10

Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

legaldesire.com2 min
AUG 13
$GOSSMedAI 8/10

Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.

tradingview.com2 min